Gene test could predict who benefits from semaglutide

NCT ID NCT06003153

Recruiting now Knowledge-focused Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This study looks at how a person's genetic makeup influences their response to oral semaglutide (Rybelsus), a drug used for type 2 diabetes. Researchers will give 125 adults with prediabetes a 14-day course of the drug and measure blood sugar, insulin, and other factors after a standardized breakfast. The goal is to understand why some people respond differently to the medication, which could lead to more personalized treatment for diabetes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: oral semaglutide (Rybelsus)
What this could lead to: If successful, this could help doctors predict who will benefit most from semaglutide based on their genes, leading to more personalized diabetes prevention.
What could go wrong: This is a small, early-phase study focused on understanding mechanisms, not proving treatment effectiveness. Results may not apply to everyone, and the 14-day treatment period is too short to assess long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENETIC PREDISPOSITION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inherited disease susceptibility metabolic disease prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENETIC PREDISPOSITION METABOLIC DISEASES TYPE 2 DIABETES

Contacts and locations

Locations

Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.